ロックインを破って,グリーンな薬局を可能にします.
Anna Shalin1,2, Miriam L Diamond2,3, Zhanyun Wang1,4
1Empa─Swiss Federal Laboratories for Materials Science and Technology, 9014 St. Gallen, Switzerland.
Environmental science & technology
|February 18, 2026
まとめ
医薬品の環境への危険性は,グリーンデザインを阻害する"ロックイン"要因のために持続しています. 誤ったリソースとインセンティブに対処することは,持続可能な薬物開発とイノベーションの鍵です.
科学分野:
- 環境科学 環境科学
- 医薬品科学 医薬品科学とは
- システム分析 システム分析
背景:
- 医薬品がもたらす環境への危険性が認識されつつある.
- よりグリーンな薬物設計と持続可能な医薬品開発の必要性.
- "デザインから良性"の原則の実施における課題.
研究 の 目的:
- 医薬品開発における障壁を特定するために"ロックイン"分析枠組みを適用する.
- グリーン・ドラッグ・デザインを阻む社会的,経済的,政治的,技術的な要因を調査する.
- これらの障壁を克服し,医薬品のイノベーションを促進するための戦略を提案する.
主な方法:
- 質的および定量的分析. 質的および定量的分析. 質的および定量的分析. 質的および定量的分析. 質的および定量的分析.
- 米国とヨーロッパの臨床試験記録の調査.
- "ロックイン"の枠組みとメドウスの介入枠組みの適用.
主要な成果:
- 2つの重要なロックインを特定しました:リソース/専門知識のタイミングの不整合と,再設計よりも新しい薬の開発を好むインセンティブ構造.
- 障壁は,将来の医薬品と既存の医薬品の両方のグリーン化に影響します.
- 分析は,政策立案者,学界,業界の利害関係者向けに具体的な勧告を提供します.
結論:
- 特定されたロックインに対処することは,医薬品におけるグリーンイノベーションの潜在能力を解き放つために極めて重要です.
- 障壁を克服することで,医薬品開発における環境安全と持続可能性が向上します.
- 医薬品のライフサイクル全体に環境の配慮を統合するために,戦略的介入が必要である.
関連する概念動画
01:18Guidelines and Strategies for Safe Computer Charting
2.7K
The guidelines and strategies provided by the American Nurses Association (ANA) and the Canadian Nurses Association (CNA) offer essential principles for ensuring safe and secure computer charting systems in healthcare settings. Let's break down each recommendation:
Maintain Confidentiality and Security:
Maintain Confidentiality and Security:
2.7K
01:26Pharmaceutical Poisoning: Potential Scenarios
19
Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
19
01:16Drug Product Stability
290
The long-term stability of drug products is critical to ensuring their quality, safety, and effectiveness over time. Stability directly influences a product's ability to maintain its intended characteristics, ensuring it performs as expected during its intended shelf life. Key attributes such as drug potency, impurities, dissolution, and other physicochemical measures of performance are tested to assess stability. These parameters indicate how well the product retains its quality over time and...
290
01:29Clinically Relevant Drug Product Specifications: Methods of Establishment
238
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
238
01:06Legal Guidelines for Documentation
2.3K
The legal guidelines for nursing documentation are essential for ensuring accurate, professional, and ethical recording of patient care. The guidelines are discussed here:
2.3K
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
26
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
26